By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Heptares 

1-3 Burtonhole Lane, Mill Hill

London    NW7 1AD  United Kingdom
Phone: 44-0-20-8906-7100 Fax: n/a


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Discovery





Company News
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016 8:36:47 AM
Heptares And Leadxpro Enter Collaboration On Powerful New Approaches To GPCR Structure Determination For Drug Discovery 6/29/2016 6:08:27 AM
Heptares Chief Scientific Officer And Co-Founder - Dr Fiona Marshall - Elected As A Fellow Of The Academy of Medical Sciences 4/28/2016 9:07:23 AM
Heptares Scientists Solve Structures Of GLP-1 And Glucagon Receptors Enabling Structure-Based Design For Metabolic Disease 4/25/2016 9:15:38 AM
Kymab And Heptares Enter Strategic Collaboration To Discover, Develop And Commercialise Novel Antibody Therapeutics 4/18/2016 8:59:30 AM
A Day After The Pfizer (PFE)-Allergan (AGN) Deal Dies, Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares 4/7/2016 6:08:48 AM
Heptares Joins Pharma Consortium Applying State Of The Art Cryo-Electron Microscopy To Advance Structure Based Drug Discovery 4/4/2016 10:29:31 AM
Sosei Subsidiary Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016 10:51:21 AM
Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016 6:08:52 AM
Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme For Industry And Academia Focused On G Protein-Coupled Receptors (GPCRS) 2/2/2016 10:11:50 AM
123456
//-->